Sinovac awarded contract to supply Anflu flu vaccine to Beijing CDC

Chinese biopharmaceuticals company Sinovac Biotech (Nasdaq: SVA) saw its share price jump 12% to $2.49 in premarket trading after it announced that it has been selected by the Beijing Centers for Disease Control and Prevention (Beijing CDC) as one of the four manufacturers to supply seasonal influenza vaccine to the citizens of Beijing for the fourth time.

Weidong Yin, chairman, president and chief executive of Sinovac, stated: “After the comprehensive evaluation of several different factors including product quality, service and price, Sinovac was selected for the fourth time, which further validates the high quality of our flu vaccine and our commitment to service as recognized by CDC customers. We look forward to working closely with the Beijing CDC to deliver our Anflu vaccine to the citizens under the vaccination campaign."

Starting in 2007, to prevent and control the seasonal flu, the Beijing CDC began purchasing the seasonal flu vaccines to immunize the elderly over 60 and the elementary and secondary school students in Beijing.